Monday, December 9, 2019

Arrowhead Pharmaceuticals Raises $266.8M In Public Offering

Pasadena-based Arrowhead Pharmaceuticals has raised $266.8M in a public offering of its stock, on the NASDAQ, where it trades as ARWR. According to Arrowhead Pharmaceuticals, it sold 4,600 shares of its common stock, at $58.00 per share. The offering was run by Goldman Sachs & Co. LLC, Jefferies LLC and Piper Jaffray & Co., along with Cantor Fitzgerald & Co., Robert W. Baird & Co. Incorporated and B. Riley FBR, Inc. Arrowhead Pharmaceutical is developing RNA-based treatments for gene related diseases, through a technique it calls gene silencing, using RNA interference, or RNAi.